Due to the particularly poor outcomes of patients with c-Myc translocation shown in some retrospective studies, these patients were reclassified as high-grade lymphoma with c-Myc translocation and bcl-2 and/or bcl-6 translocation in the 2016 WHO classification of lymphatic tumors. The gene discussed is BCL2; the disease is lymphoma.